Skip to main content
TipRanks
Go Ultimate75% OFF

Revvity (PKN) AI Stock Analysis

1 Followers
DE:PKN

Revvity

(XETRA:PKN)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Software recurring growthStrong Signals software growth and renewals add a recurring, workflow-embedded revenue stream that can improve customer retention and revenue visibility. New AI, logistics, and informatics products broaden the platform opportunity and may support durable expansion as adoption develops across laboratory customers.
Negative Factors
Compressed profitabilityAlthough earnings have recovered from the 2023 loss, profitability remains well below prior peaks and shareholder returns are modest. The lower earnings base means Revvity must sustain operational improvements and revenue growth to rebuild returns, while persistent margin compression could limit internally generated growth capacity.

Revvity (PKN) vs. iShares MSCI Germany ETF (EWG)

-20%0%20%40%60%80%100%DE:PKN+68.94%EWG+7.58%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 16.62B
Dividend Yield
0.18%
Average Volume (3M)
114
Price to Earnings (P/E)
66.2
Beta (1Y)
0.49
Revenue Growth
-0.66%
EPS Growth
7.12%
Country
Germany
Employees
11,000
Sector
Healthcare
Sector Strength
51
Industry
Medical - Diagnostics & Research

Revvity Business Overview & Revenue Model

Company Description

Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters...

Revvity Earnings Call Summary

Earnings Call Date:Nov 03, 2026(Q3-2026)|% Change Since:-0.29%|Next Earnings Date:Feb 04, 2027
Earnings Call SentimentPositive

The call was strongly positive. Highlights significantly outweighed the limited challenges, with broad-based Q3 growth, improving pharma and biotech demand, expanding AI-related demand, strong cash generation, margin expansion, and multiple upward guidance revisions. The main negatives were FX pressure, APAC and China reproductive-health challenges, the pending China immunodiagnostics divestiture, and expected moderation in certain Q4 growth rates.

Positive Updates

Strong Third-Quarter Organic Growth and Earnings Outperformance
Revvity delivered 7% pro forma organic growth in Q3, exceeding its mid-single-digit expectation. Pro forma adjusted operating margin was 29.4%, approximately 40 basis points above expectations, and pro forma adjusted EPS was $1.37, $0.08 above the midpoint of guidance and up 21% year over year.

Negative Updates

Foreign Exchange Headwind
Foreign exchange was an approximately 1% headwind to Q3 growth. For the full year, FX is expected to contribute approximately 50 basis points to revenue growth.

Company Guidance

Revvity now expects pro forma organic growth of approximately 5% in both the fourth quarter and for the full year, with FX contributing approximately 50 basis points for the full year, ACD/Labs contributing approximately 75 basis points, and 2026 pro forma revenue being approximately $2.86 billion; full year operating margins are expected to be 28.8%, net interest expense approximately $88 million, the adjusted tax rate 18%, shares outstanding 112 million, and pro forma adjusted EPS in the range of $5.40 to $5.45, which equates to approximately 12% growth year over year. For the fourth quarter, the midpoint of expected revenue is approximately $755 million, pro forma adjusted operating margins are expected to be slightly above 32%, net interest expense approximately 22 million, the adjusted tax rate approaching 20%, shares around 112 million, and the midpoint of pro forma adjusted EPS guidance $1.60; life sciences instruments are expected to grow high single digits, reagents mid single digit, Signals software closer to a mid-teens number, diagnostics mid single digits overall, immunodiagnostics up high single digits, and reproductive health at low single digits.

Revvity Risk Analysis

Revvity disclosed 24 risk factors in its most recent earnings report. Revvity reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Revvity Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:PKN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
QGENQGEN77Outperform$10.29B26.7911.04%5.30%2.17%-5.13%
TMOTMO77Outperform$256.15B36.4013.31%0.27%8.27%9.59%
AA75Outperform$48.75B34.0120.47%0.59%8.60%19.07%
ILMNILMN75Outperform$29.94B33.8831.45%―6.00%31.48%
DHRDHR73Outperform$161.75B37.788.18%0.66%5.52%25.53%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

0%50%100%DE:PKNADHRILMNQGENTMODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:PKN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:PKNRevvity, Inc.136.0057.0072.15%
AAgilent Technologies172.2228.9020.16%
DHRDanaher Corporation225.774.992.26%
ILMNIllumina202.6182.4968.67%
QGENQiagen49.755.6412.80%
TMOThermo Fisher Scientific686.79115.0120.11%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.